1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

od Joshi, K., Muhith, A., Milner-Watts, C., Obeid, M., Khakoo, S., Bhosle, J., Minchom, A.R., O'Brien, M.
Izdano u Ann Oncol (2020)

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience

od Cui, W., Yousaf, N., Bhosle, J., Minchom, A.R., Ahmed, M., McDonald, F., Locke, I., Lee, R., O'Brien, M., Popat, S.
Izdano u Ann Oncol (2020)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

od Cui, W., Milner-Watts, C., Saith, S., Bhosle, J., Minchom, A.R., Davidson, M., Page, S., Locke, I., Yousaf, N., Popat, S., O'Brien, M.E.R.
Izdano u J Thorac Oncol (2021)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine bl...

od Minchom, A R, Saksornchai, K, Bhosle, J, Gunapala, R, Puglisi, M, Lu, S K, Nimako, K, Coward, J, Yu, K C, Bordi, P, Popat, S, O'Brien, M E R
Izdano u BMJ Open Respir Res (2014)